ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2083

A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy

Massimo Radin1, Irene Cecchi2, Francesca Crisafulli3, Evandro Mendes Klumb4, Guilherme Ramires De Jesús4, Miguel Ángel Saavedra5, Geraldine Vanessa Reyes-Navarro6, Luca iaccarino7, Maddalena Larosa7, Gabriella Moroni8, Francesco Tamborini9, dario Roccatello1, Laura Andreoli3, Cecilia Beatrice Chighizola10 and Savino Sciascia2, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy, 3University of Brescia, Brescia, Italy, 4Instituto Fernandes Figueira, Rio De Janeiro, Brazil, 5Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, 6Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 7University of Padova, Padova, Italy, 8Humanitas University, Rozzano, Italy, 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 10University of Milan, Milano, Italy

Meeting: ACR Convergence 2022

Keywords: pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity and precedes clinically evident flare. Since synthesis of complement proteins increase during gestational course, it is debated whether complement levels exert a prognostic role in pregnant women with SLE.

We performed a network meta-analysis to assess the prognostic role of complement in pregnant SLE women, to evaluate the possible role of complement fluctuations during pregnancies.

Methods: Data from available prospective studies (Jan 2002-Dec 2020) investigating pregnancies in at least 50 SLE patients, excluding miscarriages before 12 weeks, werepooled together. After a systematic literature search, corresponding authors of 19 retrieved studies meetinginclusion criteria were invited to contribute with additional data, including complement C3 and C4 levels [6 months before pregnancy, at conception, 1st trimester (T1), 2nd trimester (T2), 3rd trimester (T3) and 3 months after delivery].

Results: A total of 532 SLE women from four eligible studies were included in the analysis [1-4]. Lupus Nephritis (LN) was diagnosed in 237 patients (44.5%) and Antiphospholipid Syndrome in 68 (12.8%). A total of 170 patients (32%) experienced a flare during pregnancy, defined as need of new Immunosuppressants or increase of prednisone > 9 mg/day.

Patients with LN had significantly lower mean levels of complement (C3 at conception; C3 at T1; C3 after 3 months of delivery; C4 at all timepoints except for C4 at T3). SLE patients who experienced flares during pregnancy had significantly lower mean levels of complement (all timepoints for both C3 and C4). Table 1 shows the mean C3 and C4 levels in different timepoints according to diagnosis and flare during pregnancy. Pregnancies with flare had a higher rate of maternal of fetal complications (60% vs.50.3%;p=0.03). The lowest levels of complement were observed in patients with a concomitant diagnosis of LN and presence of flare, particularly during theT1 (Figure 1). Nevertheless, both in LN and flare groups the lowest levels of C3 and C4 were documented at T1.

Conclusion: In this prospective large cohort of SLE patients low C3/C4 levels, particularly in T1, were associated with a higher frequency of flare. Lowering levels of complement, especially in T1, even within normal range might alert the treating clinicians in predicting disease course and consequently avoid flares, especially in LN.

Supporting image 1

Figure 1. Complement Levels during time in patients with Lupus Nephritis and presence, or absence, of flare during pregnancy.


Disclosures: M. Radin, None; I. Cecchi, None; F. Crisafulli, None; E. Klumb, None; G. De Jesús, None; M. Saavedra, None; G. Reyes-Navarro, None; L. iaccarino, None; M. Larosa, None; G. Moroni, None; F. Tamborini, None; d. Roccatello, None; L. Andreoli, None; C. Chighizola, None; S. Sciascia, None.

To cite this abstract in AMA style:

Radin M, Cecchi I, Crisafulli F, Klumb E, De Jesús G, Saavedra M, Reyes-Navarro G, iaccarino L, Larosa M, Moroni G, Tamborini F, Roccatello d, Andreoli L, Chighizola C, Sciascia S. A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-network-meta-analysis-on-532-sle-patients-low-complement-levels-in-the-first-trimester-predict-disease-flare-in-pregnancy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-network-meta-analysis-on-532-sle-patients-low-complement-levels-in-the-first-trimester-predict-disease-flare-in-pregnancy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology